Proliferation and differentiation of adipose tissue in prolonged lean and obese critically ill patients

[1]  G. Van den Berghe,et al.  Premorbid obesity, but not nutrition, prevents critical illness‐induced muscle wasting and weakness , 2016, Journal of cachexia, sarcopenia and muscle.

[2]  M. Singer.  Intensive Care Medicine Experimental , 2017 .

[3]  M. Jeschke,et al.  Palmitate differentially regulates the polarization of differentiating and differentiated macrophages , 2016, Immunology.

[4]  J. Granneman,et al.  Adipogenic role of alternatively activated macrophages in β-adrenergic remodeling of white adipose tissue. , 2016, American journal of physiology. Regulatory, integrative and comparative physiology.

[5]  G. Van den Berghe,et al.  Metabolic and nutritional support of critically ill patients: consensus and controversies , 2015, Critical Care.

[6]  J. Granneman,et al.  Adipose tissue plasticity from WAT to BAT and in between. , 2014, Biochimica et biophysica acta.

[7]  G. Van den Berghe,et al.  Critical illness induces nutrient-independent adipogenesis and accumulation of alternatively activated tissue macrophages , 2013, Critical Care.

[8]  J. M. Suh,et al.  PPARγ signaling and metabolism: the good, the bad and the future , 2013, Nature Medicine.

[9]  G. Van den Berghe,et al.  Impact of early parenteral nutrition on muscle and adipose tissue compartments during critical illness , 2013, Critical Care.

[10]  L. Langouche,et al.  Endocrine, Metabolic, and Morphologic Alterations of Adipose Tissue During Critical Illness* , 2013, Critical care medicine.

[11]  L. Nagy,et al.  Identification of novel markers of alternative activation and potential endogenous PPARγ ligand production mechanisms in human IL-4 stimulated differentiating macrophages. , 2012, Immunobiology.

[12]  G. Van den Berghe,et al.  Critical illness induces alternative activation of M2 macrophages in adipose tissue , 2011, Critical care.

[13]  C. Glass,et al.  PPARs and lipid ligands in inflammation and metabolism. , 2011, Chemical reviews.

[14]  G. Van den Berghe,et al.  Alterations in adipose tissue during critical illness: an adaptive and protective response? , 2010, American journal of respiratory and critical care medicine.

[15]  S. Gordon,et al.  Alternative activation of macrophages: mechanism and functions. , 2010, Immunity.

[16]  Geoff Bellingan,et al.  Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyΔ12–14 PGJ2 , 2007, Proceedings of the National Academy of Sciences.

[17]  G. Van den Berghe,et al.  Intensive insulin therapy in the medical ICU. , 2006, The New England journal of medicine.

[18]  I. Vanhorebeek,et al.  Endocrine aspects of acute and prolonged critical illness , 2006, Nature Clinical Practice Endocrinology &Metabolism.

[19]  B. Fox,et al.  Immunotherapy for melanoma: The good, the bad, and the future , 2005, Current oncology reports.

[20]  T. Lawrence,et al.  Inducible cyclooxygenase‐derived 15deoxy Δ 12‐14PGJ2 brings about acute inflammatory resolution in rat pleurisy by inducing neutrophil and macrophage apoptosis , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  B. Bistrian,et al.  Intensive insulin therapy in critically ill patients. , 2002, The New England journal of medicine.

[22]  T. Willson,et al.  Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase , 1999, Nature.

[23]  T. Willson,et al.  Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. , 1999, Nature.

[24]  B. Spiegelman,et al.  15-Deoxy-Δ 12,14-Prostaglandin J 2 is a ligand for the adipocyte determination factor PPARγ , 1995, Cell.

[25]  B. Spiegelman,et al.  15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. , 1995, Cell.